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Objective: To assess the effect and toxicity of intraperitoneal (IP) chemotherapy for epithelial ovarian
cancer and to determine the risk factors for severe toxicity.
Materials and methods: Patientswho received IP chemotherapyafteroptimaldebulking surgery forovarian
cancer between 2006 and 2012 were retrospectively reviewed. Clinical characteristics were compared
between patients with none/Grade 1 or Grade 2 toxicity and those with Grade 3 or Grade 4 toxicity.
Results: In 41 patients, the mean number of IP cycles administered was 5.6 and most patients (80.5%)
completed at least six cycles. The reasons for discontinuation were catheter-related problems (30%),
disease progression (20%), or drug-related adverse effects (30%). Grade 3 or Grade 4 toxicity was
observed in 30 patients (73.2%). The rate of neoadjuvant chemotherapy was higher in the patients with
Grade 3 or Grade 4 toxicity (37%) than in the patients without Grade 3 or Grade 4 toxicity (9%), however,
this difference was not signiﬁcant (p ¼ 0.128). During a mean follow-up period of 33.6 months, tumor
recurrence occurred in 20 (48.8%) patients and the median progression-free survival was 30.0 months.
Conclusion: Despite the high rate of adverse events, IP chemotherapy can be delivered with a high
completion rate and manageable toxicity to patients with optimally debulked ovarian cancer. Toxicity
should be closely monitored in patients who have received neoadjuvant chemotherapy until a large
prospective study can be performed to determine its inﬂuence.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Among gynecologic malignancies, ovarian cancer is the leading
cause of death worldwide, with 224,747 new cases and 140,163
deaths attributed to this disease in 2008 [1]. In the United States,
ovarian cancer was the second most prevalent malignancy of the
female genital system and the number one cause of gynecological
cancer deaths in 2012.
The amount of residual tumor remaining after surgery is a major
prognostic factor in ovarian cancer; furthermore, tumors tend to be
chemosensitive. The standard treatment for epithelial ovarian
cancer (EOC) therefore involves cytoreductive surgery followed by
intravenous (IV) chemotherapy with a platinum-based agent withnd Gynecology, Cheil General
University College of Medi-
0-380, South Korea.
bstetrics & Gynecology. Publishedor without taxane. Nevertheless, recurrence is common; 70% of
patients develop peritoneal disease and the median overall 5-year
survival rate of patients with EOC is <50%.
EOC is most likely to present as a tumor that has metastasized
throughout the peritoneal cavity. Based on this rationale, there is
increased attention on intraperitoneal (IP) chemotherapy, which
refers to direct infusion of the chemotherapeutic regimen into the
peritoneal cavity. As one of several randomized controlled trials,
the Gynecologic Oncology Group (GOG) 172 performed a milestone
study of survival outcomes. A signiﬁcant improvement in both
progression-free survival (PFS) and overall survival (OS) was
observed in the IP arm; the median PFS was 18.3 months for the IV
arm and 23.8 months for the IP arm, whereas the median OS was
49.7 months for the IV arm and 65.6 months for the IP arm [2].
Nevertheless, the standard frontline management has, for
the most part, not changed, and IP chemotherapy is still not
routinely offered in current clinical practice. The main reasons for
this are concerns about toxicity and catheter-related complications,by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic characteristics and surgical ﬁndings of 41 patients who received IP
chemotherapy following cytoreductive surgery for epithelial ovarian cancer.
Variable
Age (y) 49.1 ± 10.3
Parity 1.9 ± 1.0
BMI (kg/m2) 22.7 ± 3.0
Previous abdominal surgery 13 (31.7)
CA125 (U/mL) 783.8 ± 1662.0
Initial tumor size (cm) 9.1 ± 5.5
FIGO stage
IC 9 (22.0)
IIC 3 (7.3)
IIIA 3 (7.3)
IIIB 3 (7.3)
IIIC 23 (56.1)
Residual mass size
Grossly none 35 (85.4)
1 cm 6 (14.6)
Histology
Serous 25 (61.0)
Mucinous 5 (12.2)
Endometrioid 1 (2.4)
Clear cell 7 (17.1)
Others 3 (7.3)
Grade
1 5 (12.2)
2 6 (14.6)
3 26 (63.4)
Undetermined 4 (9.8)
Second-look surgery after IP chemotherapy 21 (51.2)
Data are presented as n (%) or mean ± standard deviation.
BMI ¼ body mass index; FIGO ¼ International Federation of Gynecology and
Obstetrics; IP ¼ intraperitoneal.
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Because of these limitations, IP chemotherapy is not widely used
even in tertiary referral centers in Korea, and only a few studies
regarding intraoperative single administration of cisplatin alone or
IP administration of these agents as a consolidation treatment after
secondary surgery have been reported [4,5]. In this study, we
assessed the effect and toxicity of IP chemotherapy for EOC and
determined the risk factors for severe toxicity during IP therapy.
Materials and methods
We retrospectively collected data from patients who had
received IP chemotherapy following cytoreductive surgery for EOC
between November 2006 and September 2012. The analysis was
restricted to newly diagnosed disease, of any stage according to the
International Federation of Gynecology and Obstetrics (FIGO),
following cytoreductive surgery with residual tumor measuring
1 cm.
Neoadjuvant chemotherapy was performed in some patients
based on their clinician's preference, and a combination agent
consisting of carboplatin (area under the curve, 5) and IV paclitaxel
(175 mg/m2) was used for three to six cycles every 21 days. After
surgical debulking, all patients were treated with six cycles of IP
chemotherapy every 21 days using a protocol similar to that used in
the GOG 172 study: IV paclitaxel (135mg/m2) over 24 hours on Day
1 followed by IP cisplatin (100 mg/m2) on Day 2 and IP paclitaxel
(60mg/m2) on Day 8. A BardPort M.R.I. implanted port (Bard Access
Systems, Inc., Salt Lake City, UT, USA) with a 9.6-Fr open-ended
single lumen catheter was used for this purpose. Before chemo-
therapeutic agents were administered, standard premedications,
including antiemetic and antihypersensitive drugs, were given, and
500 mL of warmed normal saline was infused before and after IP
cisplatin administration for hydration.
A retrospective chart review was carried out. Demographic
characteristics, pathology reports, and progressive courses related
to chemotherapy-related complications and disease progression
were obtained from medical records. All toxicities were graded
according to the Common Toxicity Criteria for Adverse Events
version 4.0. Patients with greater than Grade 1 neutropenia were
treated with granulocyte colony-stimulating factor (G-CSF) to
achieve an absolute neutrophil count of 1.5  109/L. Although our
institution has no strict guidelines, IP chemotherapy was dis-
continued and switched to an IV protocol when initial modiﬁca-
tions, such as dose reduction and cycle delays for up to 2 weeks,
failed to improve drug-related toxicity. Completion was deﬁned by
receipt of all courses planned before starting IP chemotherapy
infusion. Any Grade 3 or Grade 4 toxicity was considered to be
severe toxicity, and clinical characteristics were compared between
patients with or without severe toxicity during IP therapy.
During chemotherapy, the serum cancer antigen 125 (CA 125)
level was routinely measured before every cycle of chemotherapy,
and positron emission tomography/computerized tomography
(PET/CT) imaging was used for every three cycles of chemotherapy
to estimate disease progression. After completing the initial treat-
ment, routine follow up comprising a clinical examination and
CA125 level check were performed every 3 months for the next 2
years and every 3e6 months for the following 3 years. A PET/CT
scan was performed every 6e12 months for 5 years or when clin-
ically indicated. PFS was determined from the date of primary
surgery to the date of ﬁrst recurrence or the date of last follow up.
OS was determined from the date of primary surgery to the date of
death or the date of last follow up.
Continuous variables were compared using a paired t test, and
categorical variables were compared with a two-tailed Chi-square
test. SPSS version 12 (SPSS for Windows, Release 12; SPSS, Inc.,Chicago, IL, USA) was used for all statistical analyses. A p value
< 0.05 was taken to be signiﬁcant.
Results
All 50 EOC patients were treated with IP chemotherapy at Cheil
General Hospital and Women's Healthcare Center, Seoul, Korea
between November 2006 andMarch 2012. Nine patients who had a
residual tumor larger than 1 cm after surgery and those who had
received IP chemotherapy for a recurrent tumor were excluded
from analysis.
The mean age of the 41 patients at presentation was 49.1 years
and the mean body mass index (BMI) was 22.7 kg/m2 (Table 1).
Thirteen (31.7%) patients had undergone at least one previous
abdominal surgery. In all cases, cytoreductive surgery was per-
formed via the abdominal route, and the catheter for chemotherapy
was placed intraperitoneally at the time of the initial debulking
surgery. Most patients had FIGO Stage IIIC tumors (n ¼ 23, 56.1%),
followed by FIGO Stage IC (n ¼ 9, 22%). With respect to histology,
serous type was most common (n ¼ 25, 61%) followed by
mucinous-type tumors (n ¼ 5, 12.2%).
Neoadjuvant chemotherapy with IV paclitaxel and IV carbo-
platin was performed in 12 (29.3%) patients as follows: three cycles
in seven patients, four cycles in one patient, and six cycles in four
patients (Table 2). The mean time to start of IP chemotherapy after
surgery was 13.2 days and the mean number of IP chemotherapy
cycles administered was 5.6. Thirty one (75.6%) of the 41 patients
completed all the prescribed IP cycles. Discontinuation was
required in 10 (24.4%) cases, two of which had been scheduled to
have all nine cycles of IP chemotherapy, including three cycles of
consolidation therapy. Thus, 80.5% (n ¼ 33) of patients successfully
received IP chemotherapy for at least six cycles, and 85.4% (n ¼ 35)
of patients successfully received IP chemotherapy for at least ﬁve
cycles. However, a delay in chemotherapy duration of >3 days was
Table 2
Characteristics of neoadjuvant and adjuvant intraperitoneal chemotherapy in 41
patients.
Variable
Neoadjuvant chemotherapy (IV paclitaxel/carboplatin) 12 (29.3)
3 cycles 7 (17.1)
4 cycles 1 (2.4)
6 cycles 4 (9.8)
Adjuvant IP chemotherapy (IV paclitaxel/IP cisplatin/IP paclitaxel)
1 cycle 1 (2.4)
2 cycles 2 (4.9)
3 cycles 3 (7.3)
5 cycles 2 (4.9)
6 cycles 31 (75.6)
9 cycles 2 (4.9)
Mean number of IP chemotherapy cycles 5.6 ± 1.5
Time to start of IP chemotherapy after surgery (d) 13.2 ± 4.2
Completion of all assigned IP chemotherapy cycles 31 (75.6)
Reason for discontinuation of IP chemotherapy 10 (24.4)
Drug-related adverse events 3/10 (30)a
Disease progression 2/10 (20)
Obstruction of IP catheter 2/10 (20)
Malpositioning of IP catheter 1/10 (10)b
Patient's refusal unrelated to adverse events 2/10 (20)
Chemotherapy delay of > 3 d 23 (56.1)
Dose reduction 1 (2.4)
Data are presented as n (%) or mean ± standard deviation.
IP ¼ intraperitoneal; IV ¼ intravenous.
a All cases were due to neutropenia.
b The catheter for IP chemotherapy protruded through the vaginal vault.
Table 3
Drug-related adverse events associated with intraperitoneal chemotherapy.
Adverse events n ¼ 41 %
Neutropenia
Grades 1 and 2 5 12.2
Grades 3 and 4 28 68.3
Anemia
Grades 1 and 2 17 41.5
Grades 3 and 4 6 14.6
Thrombocytopenia (<100,000/mm3) 0
Nausea or vomiting
Grades 1 and 2 23 56.1
Grades 3 and 4 3 7.3
Diarrhea
Grades 1 and 2 2 4.9
Grades 3 and 4 3 7.3
Abdominal pain
Grades 1 and 2 18 43.9
Grades 3 and 4 1 2.4
Ileus
Grades 1 and 2 3 7.3
Grades 3 and 4 3 7.3
Neuropathy
Grades 1 and 2 10 24.4
Grades 3 and 4 1 2.4
Fever
Grades 1 and 2 16 39.0
Grades 3 and 4 0 0
Elevated liver enzymes
Grades 1 and 2 10 24.4
Grades 3 and 4 0 0
Adverse effects were scored based on the Common Toxicity Criteria for Adverse
Events criteria version 4.0.
Table 4
Comparison of clinical and surgical factors between the groups with or without
severe toxicity (any Grade 3 or Grade 4 symptoms) during intraperitoneal
chemotherapy.
Without severe
toxicity (n ¼ 11)
With severe
toxicity (n ¼ 30)
p
Age (y)a 48.5 ± 9.7 49.3 ± 10.7 0.845
Paritya 1.7 ± 1.3 2.0 ± 1.0 0.643
BMI (kg/m2)a 22.8 ± 2.5 22.6 ± 3.2 0.888
Previous abdominal surgeryb 3 (27.3) 10 (33.3) >0.99
Number of pelvic lymph
nodes retrieveda
35.5 ± 20.6 25.5 ± 17.2 0.128
Neoadjuvant chemotherapyb 1 (9.1) 11 (36.7) 0.128
Appendectomy in
cytoreductive surgeryb
10 (90.9) 21 (70.0) 0.238
Omentectomy in
cytoreductive surgeryb
11 (100) 28 (93.9) >0.99
Time to start intraperitoneal
chemotherapy after surgery (d)a
13.5 ± 2.8 13.1 ± 4.6 0.766
Data are presented as n (%) or mean ± standard deviation.
BMI ¼ body mass index.
a Based on Student t test.
b Based on two-tailed Chi-square tests.
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required in 24.4% (n ¼ 10) of cases due to toxicity. A cisplatin dose
reduction to 75 mg/m2 was required in one case.
The reasons that 10 patients failed to complete IP chemotherapy
were as follows: Grade 4 neutropenia with fever (>38.0C) in three
patients, disease recurrence in two patients, catheter obstruction in
two patients, malposition of the catheter (protrusion through the
vagina vault) in one patient, and refusal to undergo IP chemo-
therapy that was unrelated to adverse events in two patients. In
addition, one patient underwent surgery for catheter re-insertion
because of obstruction, but completed all assigned IP cycles.
Catheter-related complications were observed in 9.8% (4/41 cases)
of patients.
During the IP regimen, Grade 3 or Grade 4 toxicity was observed
in 30 patients (73.2%). The most common event was neutropenia
(n ¼ 28, 68.3%) followed by anemia (n ¼ 6, 14.6%), and severe
gastrointestinal events including nausea, vomiting, diarrhea, and
ileus (n ¼ 9, 22%; Table 3). None of the patients had thrombocyto-
penia (<100,000/mm3), but feverwas present in 16 (39%) cases, and
tumor metastasis at the chemo-port site was found in one (2.4%)
patient. A comparison of the clinical and surgical characteristics of
patients with or without severe toxicity during IP chemotherapy is
provided in Table 4. There were no signiﬁcant differences in age,
BMI, history of abdominal surgery, incidence of appendectomy or
omentectomy in cytoreductive surgery, or time to the start of the IP
regimen after surgery between these two groups. The rate of neo-
adjuvant chemotherapy was higher in patients without severe
toxicity (1 case, 9.1%) than in patients with severe toxicity (11 cases,
36.7%), however, this difference was not signiﬁcant (p ¼ 0.128).
During a mean follow-up period of 33.6 months, tumors
recurred in 20 (48.8%) patients and the average number of
chemotherapy cycles administered was 11.2. At the time of last
follow up, 27 patients were in complete remission, 11 were alive
with disease, and three had died due to disease. The median PFS
was 30.0 months [95% conﬁdence interval (CI): 6.90e53.10] and the
mean OS was 62.9 months (95% CI: 57.5e68.3). The median OS was
not reached.Discussion
In this study, we evaluated the completion rate, toxicity, and
catheter-related complications associated with IP chemotherapy
using a regimen similar to that of the GOG 172 protocol after
optimal debulking surgery for EOC. To the best of our knowledge,
this is the ﬁrst report in Korea on paclitaxelecisplatin-combined IP
chemotherapy as a ﬁrst-line adjuvant therapy. Our data indicate
that IP chemotherapy is feasible, has a high completion rate, and
has few catheter-related complications, despite the fact that Grade
3 or Grade 4 toxicity symptomswere observed in 73% of cases and a
chemotherapy delay of >3 days was required in 56% of patients.
Although we failed to identify signiﬁcant risk factors associated
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during IP chemotherapy tended to undergo more neoadjuvant
chemotherapy.
Since Weisberger et al [6] ﬁrst used nitrogen mustard for IP
chemotherapy to treat malignant ascites in 1955, there has been a
considerable need to assess the clinical outcomes and develop ideal
IP chemotherapy protocols for EOC. In 2006, the National Cancer
Institute in the United States issued a clinical statement suggesting
that patients with Stage III EOC who had received optimal
debulking surgery should be considered for IP chemotherapy. The
survival advantage conferred by IP chemotherapy has been docu-
mented in several well-designed studies as well as in a Cochrane
meta-analysis [7] that included 2119women from nine randomized
trials [2,8e15], including three randomized Phase 3 GOG trials in
2011. The study concluded that womenwere less likely to die if they
underwent chemotherapy with an IP component, with hazard ra-
tios of 0.81 (95% CI: 0.72e0.90) for OS and 0.78 (95% CI: 0.70e0.86)
for PFS. Markman et al [11] reported an OS of 63 months and a PFS
of 28 months in the GOG 114 trial of patients who received IP
chemotherapy, whereas Armstrong et al [2] recorded an OS of 65
months and a PFS of 23 months in the GOG 172 trial [2], which was
similar to our OS of 62 months and PFS of 30 months.
Despite the improvement in survival, the use of IP chemo-
therapy has not been broadly accepted due to its high cost, incon-
venient administration, high toxicity proﬁle, and consequent low
completion rate [16]. In a survey administered to American oncol-
ogists, 209 oncologists stated that themajor reason they did not use
IP chemotherapy was concern over toxicity, especially neurological
toxicity (55%), followed by nausea and vomiting (51%), nephropathy
(39%), and catheter infections (39%) [3]. However, the toxicity of IP
chemotherapy is prone to be overinterpreted. According to the
Cochrane meta-analysis, the IP route did not result in more severe
neurological or renal toxicity or hematological events such as
leukopenia, anemia, and thrombocytopenia than the IV route.
Instead, patients who received IP chemotherapy were more likely
to experience the following adverse symptoms: pain, gastrointes-
tinal events, and fever, with risk ratios of 7.47, 1.70, and 1.64,
respectively [7]. The GOG 172, which is considered a cornerstone
study for IP chemotherapy, reported a pain incidence of 11.4%
versus 1.4% for the IP arm versus the IV arm and a gastrointestinal
symptom incidence of 45.8% versus 24.3% for the IP arm versus the
IV arm.
However, the Cochrane meta-analysis had limitations. Five
[2,10e13] of the nine trials included in the analysis used different IP
and IV protocols in terms of dose and regimen. The GOG 172 study
included a higher dose of cisplatin (100 mg/m2) in the IP arm than
in the IV arm (75 mg/m2), and IP paclitaxel (60 mg/m2) was
administered on Day 8 in the IP arm, but not in the IV arm. By
contrast, Alberts et al [8] used the same dose and schedule for the IP
and IV arms (100 mg/m2 cisplatin IP or IV on day 1) in the GOG 104
study [8]. They reported a completion rate of 58% for both the IP
and IV arms, and stated that IP chemotherapy was associated with a
signiﬁcantly lower rate of hematological and neurological toxicity
and improved survival, but had a higher risk of abdominal pain
(grade  2). Similarly, Gadducci et al [9] reported that, of 100 pa-
tients, none experienced severe neurological toxicity and there
were no signiﬁcant differences in fever and gastrointestinal events
between the IP and IV arms.
In addition, although Grade 3 or Grade 4 adverse events are
common during IP chemotherapy, most of these toxicities last only
for a short time and are manageable. A nationwide observational
study in Austria [17] reported that 86% of the study patients
experienced Grade 3 or Grade 4 toxicity or other serious compli-
cations, and 60% completed IP therapy, which was higher than the
42% reported by the GOG 172 study that used the same protocol.The authors of the Austrian study [17] commented that acute side
effects were frequently recorded, and thus did not necessarily
imply that IP therapy should be discontinued. This ﬁnding is
consistent with our ﬁndings; although Grade 3 or Grade 4 toxicity
was observed in 73% of patients and a chemotherapy delay of >3
days was required in 56% of patients, 76% of the patients completed
all prescribed IP cycles. Nagao et al [18] treated patients with a
modiﬁed GOG 172 protocol using IP carboplatin and reported
similar results. In their study, 61% of the patients completed all six
cycles of the IP regimen despite the fact that 73% of the patients had
Grade 3 to Grade 4 neutropenia. In light of these results, the per-
centage of patients who complete the IP regimen in clinical practice
is likely to be higher than the 42e58% reported in the two GOG
trials [2,8].
Aggressive care for adverse events and modiﬁcations of the
protocol may decrease the severity of toxicity and thereby increase
the completion rate of IP chemotherapy. Extra IV hydration,
reduction of IP-delivered ﬂuid based on the patient's physique,
paclitaxel infusion for 24 hours on Day 1 in the GOG 172 protocol,
and use of G-CSF or new generation antiemetics are examples of
how adverse events can be treated aggressively. Moreover, studies
have investigated a variety of modiﬁcations of not only the dose
and schedule, but also the IP therapy regimen [18e20]. Oaknin et al
[19] used a modiﬁed outpatient protocol with IV paclitaxel
(175 mg/m2), and observed severe neutropenia in only 30% of pa-
tients and gastrointestinal events in 26% of patients with a rela-
tively excellent completion rate of 61%. Lesnock et al [20] reported
that 83% of patients were able to complete all six cycles of IP
therapy by dose reduction or omission of paclitaxel IV from the
GOG 172 protocol.
Nevertheless, special attention should be paid to catheter-
related complications such as obstruction, leakage, malposition,
infection, or metastasis, because these account for most instances
of IP discontinuation, and observational management is usually
ineffective. The reported incidence of catheter-related complica-
tions ranges widely from 5% to 47%, and accounts for 34e44% of all
reasons for IP discontinuation [21]. Through an analysis of the GOG
172 trial, Walker et al [22] found that 40 (20%) of the total 205
patients failed to complete IP cycles due to catheter-related prob-
lems, which accounted for 72% of all discontinued cases. They found
that failure to complete IP therapy was not associated with small
bowel resection or the timing of catheter insertion; rather, the
inability to initiate IP therapy was signiﬁcantly associated with
rectosigmoid colon resection. Therefore, consistent with other
studies [16], we concluded that insertion of a catheter at the time of
bowel resection should be avoided.
Catheter type and surgical familiarity with insertion are other
potential factors related to IP complications that have been re-
ported in the literature. Venous access devices with a single lumen,
such as the BardPort (Bard Access Systems, Inc.,), are recommended
over Tenckhoff catheters (Covidien, Inc., Mansﬁeld, MA, USA),
which was the predominant catheter type used in the GOG 172 trial
[16,22]. Furthermore, Zeimet et al [17] reported catheter-related
complications in 22% of patients, especially at the beginning of
the study. In our study, the catheter-related complication rate was
only 10%, and it accounted for 30% of discontinuations. We attribute
this low rate to the use of a BardPort (Bard Access Systems, Inc.,) in
all cases and to not performing IP therapy in patients who had
undergone any type of bowel resection.
In this study, several clinical factors including age, appendec-
tomy or omentectomy status at initial surgery, and time to start IP
chemotherapy were not associated with severe toxicity. Although
the rate of neoadjuvant chemotherapy was higher in patients with
severe toxicities than in patients without severe toxicities, there
was no signiﬁcant difference between the two groups. However,
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tical power, we assume that toxicity due to neoadjuvant drug
treatment can be cumulative, resulting in more severe toxicity
during later IP courses. Given that a higher percentage of advanced
EOC patients treated with neoadjuvant chemotherapy are potential
candidates for IP therapy compared with those undergoing upfront
surgical debulking, Le et al [23] stated that it was important to
evaluate the outcomes of IP chemotherapy in patients who received
neoadjuvant chemotherapy following cytoreduction. In their
comparative study, it was found that IP chemotherapy can be given
after upfront debulking surgery or interval debulking surgery
following neoadjuvant chemotherapy with a similar toxicity proﬁle,
except for Grade 3 or Grade 4 fatigue, which was more common in
the neoadjuvant chemotherapy group [21]. In their study, three to
four cycles of IP chemotherapy were administered in the neo-
adjuvant therapy plus debulking surgery group, whereas six cycles
of IP chemotherapy were administered to the upfront debulking
surgery group, which suggests that toxicity during IP chemotherapy
could have been underestimated in the neoadjuvant group. There-
fore, it is prudent to carefully observe and provide active supportive
care for patients who receive further neoadjuvant cycles.
There are limitations to our study. Our small sample size pre-
cludes signiﬁcant comparisons from being drawn, and our retro-
spective review of the data could have prevented us from detecting
all nonhematologic toxicities. However, our studywas homogenous
in that it was performed at a single institution using a uniform
protocol of both neoadjuvant IV and IP chemotherapy. In summary,
despite the high rate of adverse events and protocol delays, there
was a high completion rate for IP chemotherapy, and toxicity was
manageable in optimally debulked EOC patients. Given the
improvement in survival that IP chemotherapy confers, toxicity
should be carefully considered before discontinuing treatment,
with more careful observation of those patients who also receive
neoadjuvant chemotherapy. The three randomized trials [24e26]
currently underway will provide us with additional useful infor-
mation that will help inform future IP chemotherapy protocols.
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